INmune Bio Inc

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

INmune Bio reports stable financials, eyes growth in diversified programs

INmune Bio's financials remain stable, with a strategic focus on advancing key programs and achieving upcoming milestones.
The company's strengths lie in efficient trial consolidation, diversification into solid tumors, and patient-centric treatment approaches.
Challenges include operational complexities, FDA holds, and the need for successful international site enrollments.
Opportunities for growth include new program launches, expansion into different therapeutic areas, and exploring combination therapies.

INmune Bio advances Alzheimer's and cancer treatments amidst financial strength

INmune Bio's Q1 2023 performance reflects a focus on advancing treatments for Alzheimer's, cancer, and other diseases, supported by a strong financial position.
While facing challenges such as FDA clinical hold and resource allocation, the company's commitment to innovation and diversification presents growth opportunities.
With upcoming milestones and a promising pipeline, INmune Bio is poised to make significant strides in addressing critical medical needs and expanding its therapeutic reach.

INmune Bio reports Q2 loss, progresses in Alzheimer's and solid tumors

INmune Bio's Q2 2023 earnings call highlighted progress in Alzheimer's and solid tumor treatments, with positive effects observed on gray matter microstructure.
The company's financials showed a net loss but with sufficient cash reserves for operations, while upcoming milestones signal growth potential.
Challenges include managing losses, regulatory progress, and market strategies, but opportunities lie in therapeutic advancements and diversification.

INmune Bio advances Alzheimer's and cancer trials amidst financial challenges

INmune Bio made progress in patient enrollment for Alzheimer's and prostate cancer trials, with a focus on regulatory milestones. Financially, the company reported a net loss but maintains a healthy cash position. Challenges include regulatory hurdles and competition, while opportunities exist in upcoming milestones and market expansion.

INmune Bio advances Alzheimer's and prostate cancer trials amid financial challenges

INmune Bio's Q4 2023 Earnings Call highlighted progress in Alzheimer's and prostate cancer trials, with positive regulatory developments. Financially, the company reported a net loss but maintains a healthy cash position. Analyst questions focused on trial specifics and market comparisons.

INmune Bio Inc advances Alzheimer's trials and secures funding for growth

INmune Bio Inc's Q2 2024 showcased progress in Alzheimer's trials, successful fundraising, and strategic milestones ahead
The company's leadership, financial stability, and upcoming trials position it well for growth and market recognition
While facing competitive challenges and operational complexities, INmune Bio Inc remains focused on innovation and market expansion

INmune Bio excels in clinical trials, secures funding for growth

INmune Bio's Q3 2024 earnings call highlighted strong clinical progress, financial growth, and a focus on data-driven decision-making for future success.
The company's emphasis on quality standards, innovative drug delivery, and promising trial results positions them well for upcoming milestones and market impact.
While facing inquiries and challenges, INmune Bio remains confident in its programs, signaling a resilient approach to addressing industry complexities and driving growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

INmune Bio, Inc. (NASDAQ:INMB ) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Gary Nachman - Raymond James George Farmer - Scotiabank Joel Beatty - Baird Thomas Shrader - BTIG Operator Greetings, and welcome to the INmune Bio Third Quarter 2024 Earnings Call. As a reminder, this conference is being recorded.

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2024 and provides a business update.

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

“Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials” Webinar to be Held on November 7, 2024, at 1 PM ET.

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Data from Animal Model Study Demonstrate XPro™ converts m icroglia from a demyelinating cell to a remyelinating cell

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”),  a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate update.

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Boca Raton, Florida, Oct. 11, 2024 (GLOBE NEWSWIRE) --    INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that management will participate in the upcoming Maxim Healthcare Virtual Summit, to be held October 15-17, 2024.

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout 2025. It is said that the global metastatic castrate resistant prostate cancer market is projected to reach $20.70 billion by 2031. INMB completed enrollment of AD02 Phase 2 study, using XPro for patients with Alzheimer's Disease expected in Q3 of 2024, with clinical data expected 6 months after last patient recruited.

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

BOCA RATON, Fla., Sept. 26, 2024 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic Castration-Resistant Prostate Cancer (mCRPC). The Company is pleased to announce initial results from the first patient cohort in the trial.

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, today announced that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease (AD) trial demonstrated  exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB), the accepted endpoint for AD trials.

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Boca Raton, Florida, Sept. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (Nasdaq: INMB) (the “Company” or “INmune Bio”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the Company (the directors and officers and employees herein referred to as the “Insiders”), for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to an aggregate of 2,341,260 shares of common stock at a combined purchase price per share and accompanying warrant of $5.50 for the institutional investors, and $6.50 per share and accompanying warrant for the Insiders, pursuant to a registered direct offering. The warrants will be exercisable commencing six months from the date of issuance at a price of $6.40 per share and will expire five years from the initial exercise date. The warrant term may be subject to acceleration following the satisfaction of certain conditions. In the case of Insiders that participated in the offering, if the warrant termination date is on a blackout date, then the Insiders will have an additional 60 days from the termination of the blackout date to exercise the warrant.

INmune Bio Announces $13.0 Million Registered Direct Offering

Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that management will participate in the following investor conferences in September and October, 2024.

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

INmune Bio, Inc. (NASDAQ:INMB ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG George Farmer - Scotiabank Operator Greetings, and welcome to the INmune Bio Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

Company to Host Conference Call Today, August 1, at 4:30pm ET BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended June 30, 2024 and provides a business update.

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July 29, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease is pleased to be presenting results of a new and advanced proteomic analysis at this year's annual Alzheimer's Association International Conference (AAIC) in Philadelphia, PA.

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 25, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 PM EDT to discuss results for its first quarter ended June 30, 2024 and to provide a corporate update.

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Publication of detailed analysis on INKmune biology compared to cytokine stimulated cells demonstrates important anti-tumor memory like NK cell characteristics

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

INmune Bio is developing immunotherapies for cancer and Alzheimer's, focusing on TNF and NK cell platforms. Their lead drug candidate, XPro, is in Phase 2 trials for early Alzheimer's disease and has shown promising anecdotal results. INKmune, another key candidate, is in Phase 1/2 trials for metastatic castration-resistant prostate cancer.

INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

INmune Bio focuses on late-stage therapy for Alzheimer's disease and natural killer cell therapy. XPro is the main focus for Alzheimer's disease, showing promising results with ongoing phase 2 study. Financially, INMB faces cash challenges but continues to make progress with a potential transformative data readout by spring 2024.

INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection

Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

INmune Bio Inc. to Join Russell 3000® Index

INmune Bio, Inc. (NASDAQ:INMB ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer and Co-Founder Dr. Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Joel Beatty - Baird Jason McCarthy - Maxim Group Daniel Carlson - Tailwinds Research Operator Greetings and welcome to the INmune Bio First Quarter 2024 Earnings Call. At the end of the presentation, there will be a question-and-answer session.

INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update.

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, May 07, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Thursday, May 9, 2024, at 4:30 PM EDT to discuss results for its first quarter ended March 31, 2024 and to provide a corporate update.

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) --   INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimer's Disease (AD) for more than three years under the Australian compassionate use program known as the  Special Access Scheme  (SAS).

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) --   INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce the successful completion of the first cohort in the trial. Following review by the Safety Review Committee (SRC), approval has been granted to proceed with the second dose level (cohort 2). The first patient of the second cohort has been identified and will undergo screening to prepare for treatment.

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced today that it has entered into definitive agreements for the sale and purchase of 986,000 shares of its common stock and warrants to purchase up to an aggregate of 986,000 shares of its common stock at an offering price of $9.84 per share of common stock and accompanying warrant. The warrants include an acceleration clause upon positive top-line data in the Company's Phase 2 Alzheimer's Disease program (as further described  below).  The offering was priced at-the-market under Nasdaq rules based on the average of the previous 5-days' closing prices, or $9.84 per share which includes $0.125 per warrant. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of positive top-line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the “Termination Date”). The gross proceeds of this offering are approximately $9.7 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 29, 2024, subject to the satisfaction of customary closing conditions.

News for INmune Bio Inc Stock (INMB)